Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PAcMan: Polatuzumab Vedotin, Acalabrutinib and Mosunetuzumab for Untreated Mantle Cell Lymphoma
NCT07910435Phase 2Not yet recruiting
- Sponsor
- University of Washington
- Start
- Mar 2027
- Primary completion
- Jan 2033
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of polatuzumab vedotin, mosunetuzumab and acalabrutinib tablet (Variant 1) in mantle cell lymphoma (MCL), sponsored by University of Washington. Primary endpoint: Positron emission tomography complete response rate at 51 weeks. Planned start Mar 2027; status: not yet recruiting.
02
Drugs
polatuzumab vedotinmosunetuzumabacalabrutinib tablet (Variant 1)
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT07910435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07910435.